Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07454837) titled 'Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide' on March 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mirum Pharmaceuticals, Inc.
Condition:
Chronic Hepatitis D
Intervention:
Drug: Brelovitug (BJT-778)
Recruitment Status: Recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: February 26, 2026
Target Sample Size: 120
Countries of Recruitment:
Romania
United Kingdom
Romania
United Kingdom
To kn...